{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-046137","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.878200+00:00","generated_at":"2026-05-22T04:27:16.942102+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Theravance Biopharma Q1 net loss $13.6M; YUPELRI sales up 6% to $58.3M","bullets":["YUPELRI net sales of $58.3M recognized by Viatris, up 6% vs Q1 2024; Theravance's implied 35% share $20.4M.","Net loss $13.6M vs $11.7M in Q1 2024; Non-GAAP net loss from ops $8.6M vs $4.5M.","Revenue $15.4M entirely from Viatris collaboration, up 6% YoY.","Cash $131M, no debt; reaffirming all financial guidance.","CYPRESS study open label enrollment nearing completion, final patient expected by late summer; top-line data ~6 months later."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-046137","json":"https://secwatch.observer/filing/0001104659-25-046137.json","markdown":"https://secwatch.observer/filing/0001104659-25-046137.md","text":"https://secwatch.observer/filing/0001104659-25-046137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925046137/0001104659-25-046137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925046137/tm2514363d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:27:16.942102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}